Wegovy Insurance Bid Tests Korea's Obesity Care, Drug Prices and Prescribing Safeguards

A coverage application in a market growing faster than its safeguards

Novo Nordisk Korea has applied for national health insurance coverage for Wegovy, becoming the first company to seek reimbursement for a GLP-1 obesity treatment in South Korea. The application covers adults with a body mass index of at least 30, patients with cardiovascular disease, and adolescents aged 12 and older with obesity. It comes as prescriptions for Wegovy and Eli Lilly's Mounjaro reached 2,789,992 through August 2026, about 2.3 times the 1,222,574 recorded throughout 2025.

The decision could affect both patients who cannot afford treatment and a rapidly expanding market where prescribing safeguards are under scrutiny. Mounjaro and Wegovy together generated 427.2 billion won in sales in the first quarter of 2026. Meanwhile, Hanmi Pharmaceutical's newly approved efpeglenatide injection, Eppe, is entering the competition with a lower starting price.

Korea's public insurance system currently excludes obesity treatments except metabolic and bariatric surgery. Patients buying obesity medicines therefore generally pay the full cost themselves. Insurance coverage could reduce those bills for eligible patients, give the National Health Insurance Service a role in negotiating prices, and create rules for prescribing and monitoring treatment.

Kim Min-seon, president of the Korean Society for the Study of Obesity and a physician at Asan Medical Center, described the imbalance at the International Congress on Obesity and Metabolic Syndrome in September 2026.

Patients who genuinely need treatment for obesity as a disease are not using these medications, while people who do not need treatment are taking them.

Wegovy's application brings that imbalance into a formal review. The central decisions are who should qualify, how much public insurance should pay, and what checks should accompany treatment.

What must happen before insurance pays?

Wegovy must pass the Pharmaceutical Reimbursement Evaluation Committee's review, undergo price negotiations with the National Health Insurance Service, and receive approval from the Health Insurance Policy Deliberation Committee. The assessment includes whether its health benefits justify its cost and how coverage would affect insurance finances.

Cost effectiveness means comparing the money spent on treatment with the health gained. The budget assessment addresses another practical question: how much the insurance system would spend if many eligible patients started treatment. Korea must consider both the value of treating an individual and the cost of serving a large population.

Novo's application includes several patient groups, while the government has expressed particular interest in severe obesity. Health and Welfare Minister Jeong Eun-kyeong discussed Japan's approach during an August National Assembly briefing. Korea has not announced final eligibility thresholds, qualifying conditions, a patient payment rate or a decision date.

Body mass index, or BMI, is weight in kilograms divided by height in metres squared. It provides a common screening measure. Under the Korean obesity society's classifications, class II obesity means a BMI of 30 to 34.9, while class III means 35 or higher. Those categories matter because a coverage threshold of 35 would serve a narrower group than one beginning at 30.

Several dates explain how Korea reached this point:

• 2019: Korea began insurance coverage for surgery for severe obesity.
• April 2023: Wegovy received Korean approval for weight management.
• July 2024: Mounjaro received Korean approval for weight management, following approval for diabetes in June 2023.
• October 15, 2024: Wegovy became available in Korea.
• August 2025: Mounjaro entered the Korean market, while Novo reduced Wegovy supply prices.
• October 2026: Hanmi's Eppe received approval, and Wegovy's reimbursement application brought obesity drug coverage into review.

The disease burden behind the demand

The Korean Society for the Study of Obesity's 2025 Obesity Fact Sheet puts adult obesity prevalence at 38.4% in 2023, including 49.8% among men and 27.5% among women. Adult prevalence had remained around 38% for three years, although it continued rising among men.

The society's 2026 fact sheet gives a later prevalence figure of 39.2%, with the rate among men reaching 51.1%. It estimates obesity's annual socioeconomic cost at 23.4 trillion won. That measure covers a broader burden than spending on medicines, including costs associated with illness and lost economic activity.

The academic underlying fact sheet study analysed National Health Insurance Service examination data covering 17,576,389 adults from 2014 to 2023, alongside national health and nutrition survey data from 17,660 participants during 2019 to 2021. Its findings connect the coverage debate with a large, measured burden of chronic disease.

Hypertension, diabetes, high cholesterol, metabolic syndrome and high uric acid were between 1.5 and 3.6 times more prevalent among people with obesity. Metabolic syndrome is a combination of problems, such as raised blood pressure, blood sugar and abdominal fat, that increase the risk of diabetes and cardiovascular disease.

The society's fact sheet puts obstructive sleep apnea prevalence at 5.2 times that among people without obesity; the academic study gives 4.5 times. Sleep apnea causes repeated pauses in breathing during sleep. Both figures show a substantial difference relevant to deciding which accompanying illnesses might qualify someone for coverage.

Young adults also feature prominently. Class II obesity was most common among people aged 35 to 39, at 9.4%, while class III peaked among those aged 30 to 34, at about 2.6%. Soongsil University professor Han Kyung-do said severe obesity among men in their 20s and 30s had tripled over a decade. The fact sheet puts childhood and adolescent obesity at 13.8% in 2023, reaching 15.8% at age 17.

Why strong sales coexist with limited access

A Korean obesity society survey found that only 12.8% of patients with obesity had received obesity medication during the previous six months. Even among those with a BMI of at least 35, the figure was around 30%. Sales growth therefore sits alongside substantial gaps in treatment access.

Cost is a recurring reason for stopping treatment. A study of 288 people who discontinued obesity treatment found that 47.6% cited costs or insurance coverage. Estimated lowest prices for four weeks of treatment are about 210,000 won for Wegovy at 0.25 milligrams and 270,000 won for Mounjaro at 2.5 milligrams. Treatment costs can rise as doses increase.

The connection with diabetes adds another reason to consider medical need. An academic GLP-1 policy editorial, published in Diabetes & Metabolism Journal, cites the Diabetes Fact Sheet 2024: 53.8% of Korean adults with type 2 diabetes had obesity, and 11.6% had a BMI of at least 30. That editorial uses 30 as its severe obesity threshold, while the obesity society's class III category begins at 35.

The editorial recommends strict eligibility rules, different levels of reimbursement for medically vulnerable patients, stronger prescribing supervision, and care combining medication with nutrition, physical activity, behavioural treatment and psychological support. Its proposal treats access and safety as parts of the same insurance policy.

GLP-1 medicines act on pathways used by a hormone released after meals. They help regulate blood sugar and appetite and can slow the movement of food out of the stomach. Wegovy contains semaglutide. Mounjaro contains tirzepatide, which acts on both GLP-1 and another hormone pathway called GIP. Their use requires dose selection and follow-up tailored to the patient.

Prescriptions expose gaps in automatic checks

Health Insurance Review and Assessment Service data submitted to lawmakers show that prescriptions screened through Drug Utilization Review, or DUR, rose from about 50,000 in 2024 to 1.22 million in 2025 and 1.86 million in the first half of 2026. By August, the cumulative total had reached 2.79 million.

DUR supplies safety information when medicines are prescribed or dispensed, including warnings about doses, duplicate treatment and contraindications. Prescription counts measure prescribing activity, so a person receiving repeated prescriptions can appear more than once.

Mounjaro's share of combined Wegovy and Mounjaro prescriptions rose from 70.2% in January to 86.9% in August. Data obtained by another lawmaker recorded 3,122 DUR checks for Mounjaro prescriptions involving patients younger than 18 through August, adding to scrutiny of how patient eligibility is assessed.

The system lacks specific automatic warnings for combining Wegovy or Mounjaro with psychotropic appetite suppressants such as phentermine. Those older medicines act on the central nervous system. Since December 16, 2025, doctors have been required to review medication histories before prescribing them.

DUR warns when a single prescription for certain psychotropic appetite suppressants exceeds 28 days. Food and Drug Safety Ministry guidance recommends no more than four weeks at a time and a maximum treatment duration of three months for those medicines. Wegovy and Mounjaro have no equivalent prescription duration alerts, leaving regulators to consider monitoring suited to their use in chronic obesity care.

Seo Young-seok, the Democratic Party secretary on the National Assembly Health and Welfare Committee, called for broader safeguards.

We need to establish a comprehensive safety management system that can monitor combination therapy, long-term and excessive prescribing, and illegal distribution.

What the patient safety records show

Parliamentary data supplied to Democratic Party lawmaker Nam In-soon identified 4,096 patients treated for eye conditions after Wegovy or Mounjaro prescriptions. These included 104 cases of non-arteritic anterior ischemic optic neuropathy, or NAION, a condition involving reduced blood supply to the optic nerve that can cause sudden vision loss.

The records also identified 9,476 patients treated for digestive or kidney conditions: 5,973 for gallstones, 1,393 for gallbladder inflammation, 1,264 for acute pancreatitis, 511 for acute kidney failure and 335 for low blood sugar. Among this group, 378 visited emergency departments.

The analysis follows medical treatment after prescriptions. Assessing the patients' illnesses requires examining their health before treatment, other medicines and the timing of symptoms. The eye and digestive categories may include some of the same patients, so their totals cannot simply be added to calculate a unique patient count.

The Food and Drug Safety Ministry separately received 2,705 adverse event reports through June 2026, comprising 1,444 involving Wegovy and 1,261 involving Mounjaro. Commonly reported symptoms included nausea, vomiting, diarrhea, constipation, indigestion and pain at the injection site.

Prescribers left 968,399 of 995,431 Wegovy prescriptions carrying DUR warnings unchanged, or 97.3%. Among pregnancy contraindication warnings, 33.8% resulted in neither cancellation nor modification. Those figures place attention on how warnings are reviewed and documented.

Nam, a member of the National Assembly, urged assessment before prescribing and monitoring afterward.

Healthcare professionals must thoroughly review patients' medical histories before prescribing these drugs and strengthen monitoring systems to detect adverse reactions after treatment begins.

Misuse controls and the search for cheaper drugs

The Food and Drug Safety Ministry has proposed designating obesity products containing liraglutide, semaglutide and tirzepatide as medicines with potential for misuse or abuse. Advisory consultation took place in April, followed by an administrative pre-announcement in June. The measure was undergoing regulatory review, with no implementation date set.

Designation would require warning language on packaging and require a physician's prescription even in areas where pharmacies otherwise have exemptions from the separation of prescribing and dispensing. Routine access would still depend on a medical prescription.

Consultation data from the Doctor Now platform show how demand is shaping appointments. Of 735,285 applications, 93.0% involved patients selecting their preferred drug and dose beforehand. The proportion was 97.3% for Mounjaro and 69.8% for Wegovy.

Price differences are also drawing purchases overseas. A monthly supply of Mounjaro at 2.5 milligrams was reported at about 10,000 yen, roughly 85,000 won, in Japan, compared with 280,000 to 350,000 won in Korea. Japan's Ministry of Health, Labor and Welfare cut Mounjaro's price by 25% in August.

The Korea Customs Service detected 5,030 illegal obesity drug import cases between January and August 2026. Japan accounted for 63.3% and China for 21.8%. The combination of large price gaps and patients choosing doses before consultation gives regulators two connected tasks: maintaining affordable medical access and supervising how treatment is obtained.

Ep pe's rival bid rests on price and Korean trial data

Hanmi's efpeglenatide treatment, Eppe, received Korean marketing approval on October 7, 2026, in five dosage strengths. Also rendered as Epe or Efpe in English accounts, it is Korea's first domestically developed GLP-1 obesity treatment and its 45th approved domestic new drug. A launch was expected as early as October.

Ep pe is administered once a week under the skin. Hanmi's LAPSCOVERY technology helps the medicine remain in the body longer, allowing weekly dosing. In a trial involving 448 Korean patients over 40 weeks, the reported average weight reduction was 9.75%; 79.42% lost at least 5% of their weight, and 49.46% lost at least 10%. Another published trial summary gives average weight loss of 9.02% over 40 weeks.

Wegovy and Mounjaro recorded averages of 14.9% after 68 weeks and 20.9% after 72 weeks in their respective major trials. Those studies differed in duration and design, while Hanmi's evidence specifically concerns Korean patients. Hanmi has no published trial directly comparing Eppe with those rivals.

New pricing information puts Eppe's expected patient cost at 129,800 won in the first month, 228,800 won in the second, 277,200 won in the third and 299,200 won in the fourth, including value-added tax. Hanmi's supply prices range from 24,200 won per pen at 2 milligrams to 74,800 won at 10 milligrams. Final patient charges vary by medical institution.

The first month's estimate is about 80,000 won below the quoted lowest Wegovy starting price and 140,000 won below Mounjaro's. Its rising monthly costs make the expense of continued treatment as relevant as the entry price. Hanmi has set an annual sales target above 100 billion won and has not announced a reimbursement plan.

Insurance could redraw the competition

Korea's uninsured prescription obesity medicine sales totalled 450.2 billion won in the first quarter of 2026. GLP-1 injections accounted for 95.1%. Mounjaro's 323.2 billion won in sales was more than three times Wegovy's 104 billion won. At that quarterly pace, their combined annual sales would reach about 1.71 trillion won.

Novo reduced Wegovy wholesale prices before Mounjaro's arrival in August 2025, with reductions reported at roughly 10% to 44%, depending on dose. A successful insurance application would bring another pricing process: negotiation with the National Health Insurance Service. The agreed price could become a reference point for competing treatments, although effects on uninsured prices are uncertain.

Japan restricts reimbursement to patients with a BMI of at least 35, or at least 27 with two or more conditions associated with obesity. France covers 65% of treatment costs for patients with a BMI of at least 35. A similarly narrow Korean policy would leave many patients paying privately, preserving a market for lower priced alternatives.

Lilly Korea is prioritising Mounjaro coverage for diabetes rather than obesity. Its diabetes price negotiations broke down after the medicine was recognised as eligible for coverage in December 2025, and the company resubmitted its application in June 2026. That experience shows that passing an eligibility review still leaves pricing to be settled.

The decision extends beyond today's injections

Drug developers are competing on muscle preservation, tolerability and convenience as well as weight loss. A Phase 2 analysis of Regeneron's semaglutide and trevogrumab combination found about 70% less thigh muscle loss than with semaglutide alone. Roche and Zealand Pharma's petrelintide produced weight loss of up to 10.7% over 42 weeks, with 1.5% discontinuing because of gastrointestinal side effects.

A study presented at the European Association for the Study of Diabetes also found that 194 patients switching from injectable semaglutide or tirzepatide to daily oral Wegovy lost an additional 4.1% of body weight on average over three months. These developments suggest that any reimbursement framework will eventually need to assess different treatment formats and benefits.

Lee Jun-hyuk, a member of the Korean obesity society's External Cooperation and Policy Committee at Nowon Eulji Medical Center, described the policy objective.

We need a framework within public health insurance that can control the risk of misuse, monitor prescribing patterns and treatment responses, and ensure patient safety.

Wegovy's review will require Korea to connect those goals with an affordable price and defined eligibility. The practical outcome for patients will depend on all three: access to coverage, the cost left for them to pay, and medical supervision throughout treatment.

Key Points

• Wegovy is the first GLP-1 obesity treatment to seek national health insurance coverage in Korea.
• Coverage requires a reimbursement review, price negotiations and final policy approval. Eligibility and timing remain undecided.
• Combined Wegovy and Mounjaro prescriptions reached 2.79 million through August 2026, about 2.3 times the 2025 total.
• Official obesity data show a substantial burden of chronic disease, while patient surveys identify limited treatment access and financial pressure.
• Prescribing reviews have identified gaps in combination treatment alerts and follow-up after safety warnings.
• Hanmi's Eppe adds a lower priced competitor, with expected costs rising from 129,800 won in month one to 299,200 won in month four.
• The insurance decision could connect lower patient costs with negotiated prices and stronger treatment oversight.